Ibandronate in profile: drug characteristics and clinical efficacy

Bibliography

• Kalpakcioglu BB, Morshed S, Engelke K, Genant HK. Advanced imaging of bone macrostructure and microstructure in bone fragility and fracture repair. J Bone Joint Surg Am 2008;90(Suppl 1):68-78
   PubMedGoogle Scholar
• Boutroy S, Bouxsein Ml, Munoz F, Delmas PD. Non invasive measurement of trabecular architecture by 3D-pQCT discriminates osteopenic women with and without fractures [abstract SA360]. J Bone Miner Res 2005;20(Suppl 1):S91
   Web of Science ®Google Scholar
• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:S12-7
   PubMed Web of Science ®Google Scholar
• Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10
   PubMed Web of Science ®Google Scholar
• Gullberg B, Johnell O, Kanis Ja. World-wide projections for hip fracture. Osteoporos Int 1997;7:407-13
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005 - 2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16:229-38
   PubMed Web of Science ®Google Scholar
• Bonviva 150mg film-coated tablets. Summary of Product Characteristics 2006
   Google Scholar
• Bonviva 3mg/3ml solution for injection in pre-filled syringe. Summary of Product Characteristics 2006
   Google Scholar
• Bondronat concentrate for solution for infusion. Summary of Product Characteristics 2007
   Google Scholar
• Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-11
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42
   PubMed Web of Science ®Google Scholar
• Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. In: Heersche JNM, Kanis JA, editors, Bisphosphonates: structure-activity relationships and therapeutic implications, in bone and mineral research. Elsevier Publishing Co.: Amsterdam; 1994. p. 265-306
   Google Scholar
• Ebetino FH, Dansereau SM. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG, editors, Bisphosphonate antiresorptive structureactivity relationships, in bisphosphonate on bones. Elsevier Publishing Co.: Amsterdam; 1995. p. 139-53
   Google Scholar
• Luckman SP, Coxon FP, Ebetino FH, et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78
   PubMed Web of Science ®Google Scholar
• Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
   PubMed Web of Science ®Google Scholar
• Ravn P, Clemmesen B, Riis Bj, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose finding study. Bone 1996;19:527-33
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. J Clin Endocrinol Metab 2005;90:5018-24
   PubMed Web of Science ®Google Scholar
• Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103:298-307
   PubMed Web of Science ®Google Scholar
• Christiansen C, Tankó LB, Warming L, et al. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 2003;14:609-13
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Gieschke R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 2006;7:827-36
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Ronald Emkey, Colin Neate, Charles H Chesnut. Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: results from a sub-analysis of a pivotal study [Abstract 152]. Bone 2008;42(Suppl. 1):S86
   Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the Monthly Oral IBandronate in LadiEs (MOBILE) study. J Bone Miner Res 2005;20:1315-22
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheum 2008 in press
   PubMedGoogle Scholar
• Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13
   PubMed Web of Science ®Google Scholar
• Collette J, Reginster J-Y, Zerbini CAF, et al. Reduction in bone remodelling markers with monthly oral ibandronate (150mg) and weekly alendronate (70mg): results from the MOTION study [abstract P474]. Osteoporos Int 2008;19(Suppl 1):S207
   Google Scholar
• Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-9
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 2006;54:1838-46
   PubMed Web of Science ®Google Scholar
• Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheum 2008;35:488-97
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Pfeilschifter J, Rachela Grant, et al. Continuing improvements in the efficacy of quarterly intravenous ibandronate injection: DIVA study long-term extension [abstract 307Th]. Bone 2007;40(Suppl 2):S301
   Google Scholar
• Cranney A, George Wells, Jonathan Adachi. Non-vertebral fracture reduction with high- versus low-dose ibandronate: a meta-analysis of individual patient data [abstract LB0004]. Ann Rheum Dis 2007;66(Suppl 2):681
   Google Scholar
• Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45
   PubMed Web of Science ®Google Scholar
• Epstein S, Delmas PD, Emkey R, et al. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Maturitas 2006;54:1-10
   PubMed Web of Science ®Google Scholar
• Brown JP, Burckhardt P, Reid IR, et al. Zoledronic acid, at a total annual dose of 4 mg, increases bone density at all sites and stably reduces bone turnover for one year when administered as a single or a 3-monthly intravenous injection in postmenopausal osteoporosis [abstract F353]. J Bone Miner Res 2001;16(Suppl 1):S218
   Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Kraj M, PogłódR, Maj S, et al. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm 2002;59:478-82
   PubMedGoogle Scholar
• Berenson JR. Zoledronic acid in cancer patients with bone metastases: results of phase I and II trials. Semin Oncol 2001;28(Suppl 6):25-34
   PubMed Web of Science ®Google Scholar
• Miller PD, Ward P, Pfister T, et al. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheum 2008; in press
   PubMedGoogle Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72
   PubMed Web of Science ®Google Scholar
• Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006;119(Suppl 1):S12-7
   PubMed Web of Science ®Google Scholar
• Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(Suppl 1):S18-24
   Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E. The PERSIST investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905
   PubMed Web of Science ®Google Scholar
• Silverman S, Joyce A Cramer, John Sunyecz, et al. Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12 month results from two retrospective databases [abstract W366]. J Bone Miner Res 2007;22(Suppl 1):S454
   Google Scholar
• Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007;23:2193-203
   PubMed Web of Science ®Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
   PubMed Web of Science ®Google Scholar
• Piziak VK, Babbitt AM, Kohles J, Lewiecki M. Comparable adherence and improvement in GI tolerability with monthly oral and quarterly IV ibandronate in patients who discontinued previous bisphosphonates because of GI intolerance [abstract W362]. J Bone Miner Res 2007;22(Suppl 1):S453
   Google Scholar
• Garcia-Hernández PA, Carranza-Lira S, de la Peña-Rodríguez P, et al. The impact of bonemarker feedback on adherence to once monthly ibandronate treatment for post-menopausal osteoporosis (PMO) in Mexican and Chilean patients (BOHEMIA Study) [abstract T391]. J Bone Miner Res 2007;22(Suppl 1):S330
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis. Curr Med Res Opin 2005;21:1895-903
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomised, crossover study (BALTO II). Joint Bone Spine 2008;75:303-10
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Blumentals WA, Barr CE, et al. Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study [Abstract OC17]. Osteoporos Int 2008;19(Suppl. 1):S9
   Google Scholar
• Hochberg MC, Hochberg MC, Greenspan S, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92
   PubMed Web of Science ®Google Scholar